Patents by Inventor Thomas S. Arrhenius

Thomas S. Arrhenius has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CS-1 peptidomimetics, compositions and methods of using the same
    Patent number: 6117840
    Abstract: The present invention contemplates a peptide that inhibits the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compositions containing a contemplated peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory peptide are also disclosed.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: September 12, 2000
    Assignee: Cytel Corporation
    Inventors: Thomas S. Arrhenius, Mariano J. Elices, Federico C. A. Gaeta
  • CS-1 peptidomimetic, compositions and methods of using the same
    Patent number: 6103870
    Abstract: The present invention contemplates a peptide that inhibits the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compositions containing a contemplated peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory peptide are also disclosed.
    Type: Grant
    Filed: September 3, 1997
    Date of Patent: August 15, 2000
    Assignee: Cytel Corporation
    Inventors: Thomas S. Arrhenius, Mariano J. Elices, Federico C. A. Gaeta
  • CS-1 peptidomimetics, compositions and methods of using the same
    Patent number: 5936065
    Abstract: The present invention contemplates a compound defined by the following formula: ##STR1## that inhibits the binding between the VLA-4 and the fibronectin CS-1 compound. Pharmaceutical compositions containing a contemplated compound and methods for treating immunoinflammatory conditions using the compound are also disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 10, 1999
    Assignee: Cytel Corporation
    Inventors: Thomas S. Arrhenius, Mariano J. Elices, Federico C. A. Gaeta
  • Cyclic CS-1 peptidomimetics, compositions and methods of using same
    Patent number: 5869448
    Abstract: The present invention contemplates a cyclic peptide that inhibits the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compositions containing a contemplated cyclic peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory cyclic peptide are also disclosed.
    Type: Grant
    Filed: August 25, 1995
    Date of Patent: February 9, 1999
    Assignee: Cytel Corporation
    Inventors: Thomas S. Arrhenius, Anna Tempczyk, Mariano J. Elices, Zhong-Li Zheng
  • CS-1 peptidomimetics, compositions and methods of using same
    Patent number: 5821231
    Abstract: The present invention contemplates a compound defined by the following formula: ##STR1## that inhibits the binding between the VLA-4 and the fibronectin CS-1 compound. Pharmaceutical compositions containing a contemplated compound and methods for treating immunoinflammatory conditions using the compound are also disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 13, 1998
    Assignee: Cytel Corporation
    Inventors: Thomas S. Arrhenius, Mariano J. Elices, Federico C. A. Gaeta
  • Cyclic CS-1 peptidomimetics, compositions and methods of using same
    Patent number: 5811391
    Abstract: The present invention contemplates a cyclic peptide that inhibits the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compositions containing a contemplated cyclic peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory cyclic peptide are also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 22, 1998
    Assignee: Cytel Corporation
    Inventors: Thomas S. Arrhenius, Mariano J. Elices, Anna Tempczyk, Zhong-Li Zheng
  • CS-1 peptidomimetics, compositions and methods of using the same
    Patent number: 5770573
    Abstract: The present invention contemplates a compound defined by the following formula: ##STR1## that inhibits the binding between the VLA-4 and the fibronectin CS-1 compound. Pharmaceutical compositions containing a contemplated compound and methods for treating immunoinflammatory conditions using the compound are also disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 23, 1998
    Assignee: Cytel Corporation
    Inventors: Thomas S. Arrhenius, Mariano J. Elices, Federico C.A. Gaeta
  • CS-1 peptidomimetics, compositions and methods of using the same
    Patent number: 5688913
    Abstract: The present invention contemplates a peptide that inhibits the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compositions containing a contemplated peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory peptide are also disclosed.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: November 18, 1997
    Assignee: Cytel Corporation
    Inventors: Thomas S. Arrhenius, Mariano J. Elices, Federico C. A. Gaeta
  • Immunosuppressant peptides
    Patent number: 5679640
    Abstract: Peptide compositions are provided which bind MHC molecules of interest and inhibit T cell activation. The peptide compositions of the present invention comprise various isosteres of naturally occurring amino acid sequences. Such compositions may be used to treat diseases associated with particular DR alleles, including autoimmune diseases such as rheumatoid arthritis.
    Type: Grant
    Filed: March 8, 1995
    Date of Patent: October 21, 1997
    Assignees: Cytel Corporation, Sandoz Ltd.
    Inventors: Federico C. A. Gaeta, Michael F. Powell, Howard M. Grey, Alessandro D. Sette, Thomas S. Arrhenius